California-based AI drug discovery startup, Hexagon Bio, has raised USD 77.3 million in a Series B funding round which saw participation from existing investors, The Column Group and Two Sigma Ventures, as well as new investors, including Canada Pension Plan Investment Board (CPP Investments).
The proceeds will be directed toward expanding its team across various fields and enhancing the capabilities of its drug discovery platform.
Founded in 2016, Hexagon Bio engages in the discovery of medicines based on the global metagenome—a collection of the genetic material of all the microorganisms present in various ecosystems such as soil, water, and the human body. It leverages its proprietary platform that combines AI/ML technologies, genomics, chemistry, and synthetic biology to accelerate drug-target prediction, DNA sequencing, and compound production.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.